Dexlansoprazole Sustained Release Capsule Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

Dexlansoprazole Sustained Release Capsule Market Size
The global Dexlansoprazole Sustained Release Capsule market was valued at US$ 298 million in 2022 and is anticipated to reach US$ 428.1 million by 2029, witnessing a CAGR of 5.3% during the forecast period 2023-2029.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-25J14249/Global_Dexlansoprazole_Sustained_Release_Capsule_Market_Research_Report_2023

Dexlansoprazole Sustained Release Capsule Market
Dexlansoprazole sustained-release capsules were approved by the U.S. FDA in January 2009, under the trade name DEXILANT. For the treatment of heartburn caused by non-erosive gastroesophageal reflux disease (GERD), erosive esophagitis (EE) and maintenance treatment after healing of erosive esophagitis, all of which are administered once a day.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Dexlansoprazole Sustained Release Capsule is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Dexlansoprazole Sustained Release Capsule is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Dexlansoprazole Sustained Release Capsule include TAKEDA PHARM, PAR PHARM and TWI PHARM, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dexlansoprazole Sustained Release Capsule, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dexlansoprazole Sustained Release Capsule.
The Dexlansoprazole Sustained Release Capsule market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Dexlansoprazole Sustained Release Capsule market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dexlansoprazole Sustained Release Capsule manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-25J14249/Global_Dexlansoprazole_Sustained_Release_Capsule_Market_Research_Report_2023

Segment by Type
• 30MG
• 60MG

Segment by Application
• Hospital
• Clinic

By Company
TAKEDA PHARM, PAR PHARM, TWI PHARM

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-25J14249/global-dexlansoprazole-sustained-release-capsule

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.